AEON Biopharma, Inc. to Post Q1 2024 Earnings of ($0.31) Per Share, HC Wainwright Forecasts (NASDAQ:AEON)

AEON Biopharma, Inc. (NASDAQ:AEON) – Equities research analysts at HC Wainwright lifted their Q1 2024 earnings estimates for shares of AEON Biopharma in a research report issued to clients and investors on Wednesday, April 17th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.31) per share for the quarter, up from their previous forecast of ($0.39). HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for AEON Biopharma’s current full-year earnings is ($1.54) per share. HC Wainwright also issued estimates for AEON Biopharma’s Q2 2024 earnings at ($0.31) EPS, Q3 2024 earnings at ($0.32) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.18) EPS and FY2025 earnings at ($1.16) EPS.

AEON Biopharma (NASDAQ:AEON) last released its quarterly earnings data on Friday, March 29th. The company reported ($0.71) EPS for the quarter.

AEON Biopharma Trading Down 28.7 %

AEON stock opened at $4.66 on Friday. AEON Biopharma has a 12 month low of $3.37 and a 12 month high of $17.17. The firm has a 50-day moving average of $10.55 and a two-hundred day moving average of $7.77.

Institutional Trading of AEON Biopharma

Hedge funds have recently bought and sold shares of the business. Northern Trust Corp raised its holdings in AEON Biopharma by 53.4% in the 4th quarter. Northern Trust Corp now owns 49,819 shares of the company’s stock valued at $359,000 after acquiring an additional 17,341 shares during the last quarter. Formidable Asset Management LLC acquired a new stake in shares of AEON Biopharma during the 3rd quarter worth approximately $360,000. Vanguard Group Inc. acquired a new stake in shares of AEON Biopharma during the 3rd quarter worth approximately $1,085,000. Finally, Atalaya Capital Management LP acquired a new stake in shares of AEON Biopharma during the 3rd quarter worth approximately $19,827,000. Institutional investors and hedge funds own 22.78% of the company’s stock.

About AEON Biopharma

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.